002275.SHE Guilin Sanjin Pharmaceutical Co Ltd
- Market cap
- CNY 9.99B
- P/E
- 21.5x
- P/B
- 2.61x
- ROE
- 14.8%
- Dividend yield
- 3.41%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002275.SHE undervalued?
Graham number002275.SHE trades 58.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guilin Sanjin Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Guilin Sanjin Pharmaceutical Co Ltd yet.
Guilin Sanjin Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guilin Sanjin Pharmaceutical Co Ltd
Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, manufacturing, and sale of traditional Chinese medicines in China and internationally. The company offers Sanjin Tablets, Sanjinpian, Guilin Watermelon Frost, Watermelon Frost Throat Lozenges, Guilin Watermelon Frost Lozenges, Watermelon Frost Throat Clearing Lozenges, Vertigo Relief Tablets/Granules, Gecko Asthma Relief Capsules, Lamotrigine Tablets (Anxian), Naomaitai Capsules, Yuye Detoxification …
Full company profileGuilin Sanjin Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guilin Sanjin Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.53B | 1.62B | 1.58B | 1.64B | 1.57B | 1.74B | 1.96B | 2.17B | 2.19B | 2.05B | 1.93B |
| Gross Profit | 1.12B | 1.23B | 1.15B | 1.20B | 1.12B | 1.28B | 1.39B | 1.57B | 1.58B | 1.56B | 1.45B |
| Operating Income | 467M | 565M | 498M | 469M | 355M | 429M | 447M | 518M | 645M | 568M | 669M |
| EBITDA | 515M | 592M | 553M | 556M | 394M | 413M | 412M | 576M | 571M | 656M | 604M |
| Net Income | 394M | 464M | 413M | 392M | 277M | 344M | 330M | 421M | 522M | 433M | 499M |
| EPS | 0.67 | 0.79 | 0.70 | 0.67 | 0.48 | 0.60 | 0.56 | 0.72 | 0.89 | 0.74 | 0.85 |
| Balance Sheet | |||||||||||
| Total Assets | 2.87B | 3.23B | 3.41B | 3.42B | 3.88B | 4.10B | 3.96B | 3.94B | 4.23B | 4.26B | 4.18B |
| Total Liabilities | 444M | 576M | 599M | 600M | 923M | 1.26B | 1.15B | 1.12B | 1.22B | 1.07B | 812M |
| Shareholders' Equity | 2.43B | 2.65B | 2.81B | 2.82B | 2.96B | 2.84B | 2.81B | 2.82B | 3.01B | 3.19B | 3.37B |
| Cash & Short-term Investments | 720M | 734M | 1.22B | 1.24B | 1.72B | 1.70B | 1.43B | 1.36B | 1.68B | 991M | 1.00B |
| Total Debt | 50.0M | 100M | 100M | 184M | 400M | 609M | 466M | 409M | 476M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 537M | 388M | 552M | 468M | 598M | 410M | 529M | 549M | 588M | 708M | - |
| Capital Expenditure | 65.4M | 61.5M | 90.0M | 226M | 205M | 144M | 62.3M | 76.4M | 82.2M | 86.9M | 227M |
| Free Cash Flow | 471M | 326M | 462M | 242M | 393M | 266M | 466M | 473M | 506M | 621M | 305M |
| Ratios | |||||||||||
| ROE | 16.2% | 17.5% | 14.7% | 13.9% | 9.4% | 12.1% | 11.7% | 15.0% | 17.3% | 13.6% | 14.8% |
| ROA | 13.7% | 14.4% | 12.1% | 11.5% | 7.1% | 8.4% | 8.3% | 10.7% | 12.3% | 10.2% | 11.9% |
| Net Profit Margin | 25.8% | 28.7% | 26.1% | 23.9% | 17.7% | 19.7% | 16.8% | 19.4% | 23.8% | 21.2% | 25.9% |
| Debt to Equity | 0.02x | 0.04x | 0.04x | 0.07x | 0.14x | 0.21x | 0.17x | 0.15x | 0.16x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guilin Sanjin Pharmaceutical Co Ltd dividends
- Dividend yield
- 3.41%
- Forward dividend
- 0.50 CNY
- Payout ratio
- 78.7%
- Ex-dividend date
- Jun 4, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 341M | 0.58 | 78.7% |
| 2024 | CNY 336M | 0.57 | 64.5% |
| 2023 | CNY 428M | 0.73 | 101.5% |
| 2022 | CNY 529M | 0.90 | 160.5% |
| 2021 | CNY 460M | 0.80 | 133.9% |
| 2020 | CNY 132M | 0.23 | 47.8% |
| 2019 | CNY 204M | 0.35 | 52.0% |
| 2018 | CNY 239M | 0.40 | 57.8% |
| 2017 | CNY 241M | 0.41 | 51.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 13:10 on Apr 21, 2011.
Who owns Guilin Sanjin Pharmaceutical Co Ltd
- Insiders 77.55%
- Institutions 0.52%
- Public & others 21.93%
- Shares outstanding 588M
- Free float 136M
Guilin Sanjin Pharmaceutical Co Ltd company profile
- Company name
- Guilin Sanjin Pharmaceutical Co Ltd
- Ticker
- 002275.SHE
- ISIN
- CNE100000DY9
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jul 10, 2009
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,556
- Fiscal year end
- December
- Address
- No. 9, Renmin South Road, Guilin, China, 541199
- Phone
- 86 77 3582 9106
- Website
- sanjin.com.cn
About Guilin Sanjin Pharmaceutical Co Ltd
Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, manufacturing, and sale of traditional Chinese medicines in China and internationally. The company offers Sanjin Tablets, Sanjinpian, Guilin Watermelon Frost, Watermelon Frost Throat Lozenges, Guilin Watermelon Frost Lozenges, Watermelon Frost Throat Clearing Lozenges, Vertigo Relief Tablets/Granules, Gecko Asthma Relief Capsules, Lamotrigine Tablets (Anxian), Naomaitai Capsules, Yuye Detoxification Granules, and Compound Tianqi Stomach Pain Capsules, Soothing Throat Spray, Guilin Watermelon Frost Capsules, NaoMaiTai Capsules, Dizziness Relief Granules, Sanqi Blood Damage Relief Capsules, Sanqi Blood Injury Relief Powder, Compound Luo Han Guo Lung-Clearing Granules, Compound Monk Fruit Lung-Clearing Syrup, Compound Red Root Herb Tablets, Shuanghu Swelling and Pain Relief, Liver and Kidney Tonifying Granules, and Jade Leaf Detoxification Granules. Its products are used in various therapeutic areas, such as urinary system diseases, oral and pharyngeal medications, throat medication, cardiovascular and cerebrovascular disease medications, nervous system diseases, respiratory disease, digestive system disease, internal medicine drugs, musculoskeletal system diseases, and tonifying drugs. Guilin Sanjin Pharmaceutical Co., Ltd. was incorporated in 2001 and is headquartered in Guilin, China. Guilin Sanjin Pharmaceutical Co., Ltd. operates as a subsidiary of Guilin SanJin Group Co.,Ltd.
Guilin Sanjin Pharmaceutical Co Ltd management
6- Mr. Xun ZouChairman of the Board & President · born 1976
- Mr. Chun LiFinancial Officer, VP & Secretary of the Board · born 1977
- Mr. Jinqian XuPersonnel Administration Director, Manager of HR Mgmt. Dept. & Director · born 1971
- Mr. Zhun ZouVP & Non-Independent Director · born 1980
- Mr. Jingdu LeiDirector & VP · born 1970
- Jie ZengAccounting Supervisor